The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on March 22, 2018 at the USPTO Headquarters (Alexandria, VA). The agenda for the meeting is as follows: • Welcoming and Opening Remarks (10:00 – 10:10 am EDT) — Daniel Sullivan and Andrew Wang, Directors, TC1600, USPTO • Obviousness of Biologics: Identifying the Biggest Challenges (10:10 – 11:00 am) — Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum LLP • 103 KSR Rationales (11:00 – 11:50 am) — Lora Driscoll, QAS, TC1600, USPTO • Lunch (11:50 am – 12:50 pm) • 112(f)-New Form Paragraphs…Original Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.